ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Molecular Bacterial Pathogenesis
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1616164
This article is part of the Research TopicImproving the Gut Microbiome: Applications of Fecal Transplantation in Disease - Volume IIView all 4 articles
Propionic Acid Mediates the Renoprotective Effects of Fecal Microbiota Transplantation against Ischemia-Reperfusion Injury via upregulating GPR43
Provisionally accepted- 1General Hospital of Central Theater Command of Chinese People’s Liberation Army, Wuhan, China
- 2China Peptide and Life ScienceResearch Institute, Wuhan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Kidney ischemia-reperfusion injury (IRI) is a critical contributor to acute kidney injury (AKI), characterized by exacerbated inflammation and apoptosis following reperfusion. This study investigates the renoprotective effects of fecal microbiota transplantation (FMT) and its underlying mechanisms in a rat model of kidney IRI. Sprague-Dawley rats (SDRs) subjected to bilateral kidney ischemia (45 min) followed by reperfusion were prophylactically treated with FMT derived from guinea pigs or propionic acid supplementation. Kidney function, histopathology, inflammatory markers, apoptosis, proliferation and gut microbiota composition were systematically evaluated. These findings demonstrate that FMT alleviates IRI by reshaping gut microbiota to enhance propionic acid production, which modulates inflammation and apoptosis via GPR43 signaling. This study provides novel insights into microbiota-targeted therapies for kidney IRI, highlighting propionic acid as a potential therapeutic agent.
Keywords: fecal microbiota transplantation, Acute Kidney Injury, ischemia-reperfusion injury, short-chain fatty acids, Lachnospiraceae
Received: 22 Apr 2025; Accepted: 03 Sep 2025.
Copyright: © 2025 Yu, Liu, Wang, Zhou, Liu, Wang, Xie, Tian, Xu, Wang, Zhao, Wang, Zhang, Chen, Gao and Pan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Dongliang Chen, China Peptide and Life ScienceResearch Institute, Wuhan, China
Lei Gao, General Hospital of Central Theater Command of Chinese People’s Liberation Army, Wuhan, China
Tiejun Pan, General Hospital of Central Theater Command of Chinese People’s Liberation Army, Wuhan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.